ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Terns Pharmaceuticals Inc

Terns Pharmaceuticals Inc (TERN)

6.00
0.14
(2.39%)
Closed May 25 4:00PM
6.06
0.06
(1.00%)
After Hours: 7:57PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
6.06
Bid
6.06
Ask
6.29
Volume
440,985
5.80 Day's Range 6.05
3.26 52 Week Range 13.03
Market Cap
Previous Close
5.86
Open
5.90
Last Trade Time
Financial Volume
$ 2,635,777
VWAP
5.977
Average Volume (3m)
957,445
Shares Outstanding
64,651,693
Dividend Yield
-
PE Ratio
-4.30
Earnings Per Share (EPS)
-1.4
Revenue
-
Net Profit
-90.21M

About Terns Pharmaceuticals Inc

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Terns Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TERN. The last closing price for Terns Pharmaceuticals was $5.86. Over the last year, Terns Pharmaceuticals shares have traded in a share price range of $ 3.26 to $ 13.03.

Terns Pharmaceuticals currently has 64,651,693 shares outstanding. The market capitalization of Terns Pharmaceuticals is $387.91 million. Terns Pharmaceuticals has a price to earnings ratio (PE ratio) of -4.30.

TERN Latest News

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

FOSTER CITY, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

Interim data from initial dose escalation cohorts from Phase 1 CARDINAL trial of TERN-701 (allosteric BCR-ABL) in CML expected in 2H24 Top-line data from Phase 1 trial of TERN-601 (oral GLP-1...

Terns Pharmaceuticals Announces Leadership Changes

FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024

FOSTER CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor class Pharmacokinetic data show no clinically significant...

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio...

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Interim data from initial dose escalation cohorts from Phase 1 trial of TERN-701 (allosteric BCR-ABL) for treatment of CML expected in second half of 2024 Top-line data from Phase 1 trial of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.06-0.9803921568636.126.3595.645848686.03523238CS
41.3829.48717948724.686.3594.627620895.71088524CS
12-1.3-17.66304347837.368.684.329574456.29584678CS
262.4768.80222841233.598.683.597820166.31611648CS
52-5.91-49.37343358411.9713.033.267337226.8874942CS
156-9.8-61.79066834815.8619.971.453803137.09969311CS
260-10.89-64.247787610616.9528.361.453608267.68719415CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

Discussion

View Full Feed
sunspotter sunspotter 7 minutes ago
“ I wonder if there will be more insider buying at these prices?”

MORE insider buying??

I must have missed the preceding insider buying.

In my experience penny stock scams controlled by French Canadian organised crime rings- that would be PKTX - only se
PKTX
Aimless Blade Aimless Blade 9 minutes ago
AI is just one proposed type of icing on the cake…
The cake is a massive overhaul of data processing using light to transmit data.

Electro-optic polymers in silicon photonics are going to exponentially increase bits per kilowatt hour, making many things possible.
LWLG
HippyTrades HippyTrades 9 minutes ago
Yet it seems to always garner your attention
AXXA
HippyTrades HippyTrades 10 minutes ago
Same old song and dance
AXXA
RichieBoy RichieBoy 12 minutes ago
No I didn't listen but that's just me to a T, selective hearing 🤫

I averaged down for a few weeks while you were cursing me under your breath. Wasn't easy needed lots of patience and I dare say some skill involved I didn't know I had. But enough of me tooting my own horn.
AFFU
sunspotter sunspotter 12 minutes ago
“ You know when almost an entire board hates something it’s probably time to buy it”

Yeah. That’s exactly how it works.

Well, that’s how it works if you’re a moron who doesn’t mind giving their money to JF Amyot and his organised crime pals.
WDRP
Flobewan Flobewan 19 minutes ago
How about rabbits and raccoons
LovePennyStock LovePennyStock 20 minutes ago
It's in expert market already, don't think it will be delisted from OTC even with no trades for 30 days. No worries .
PSPW
New money98 New money98 20 minutes ago
I asked a simple question...were shares cancelled??? Yes or No!!!!
MrMyers MrMyers 21 minutes ago
Convertible note terms?
GTCH
Threeflight Threeflight 25 minutes ago
Outstanding Shares
The number of shares outstanding of our Common Stock was:
As of 02/29/2024, the number of shares outstanding of our Common Stock was:
966,442,572
As of 5/31/2023, the number of shares outstanding of our Common Stock was:
966,442,57

AVVH
ignatiusrielly35 ignatiusrielly35 28 minutes ago
I’m not sure what you’ve been smoking. Please link to the better placebo-controlled results. It’s okay, we understand that you can’t. You’re a hack.
AVXL
MrMyers MrMyers 29 minutes ago
Please elaborate on the changes you anticipate beginning next Tuesday. I always appreciate your DD and thinking.
GTCH
MrMyers MrMyers 31 minutes ago
Thanks for the DD regarding real potential opportunities for GBT’s chip IP.
GTCH
disgusted investor disgusted investor 32 minutes ago
seems to be people willing to sell very cheap . I wonder if there will be more insider buying at these prices?
PKTX
MrMyers MrMyers 33 minutes ago
👏I concur!
GTCH
Genz2 Genz2 34 minutes ago
The government should make the activation of TPMs and SEDs mandatory!! It’s like saying it’s okay to drive without a seatbelt fastened!! The seatbelt was put in cars to be used and people just didn’t wear them all the time and now we all know to put on our seatbelts before we drive because it’s th
janice shell janice shell 35 minutes ago
America was already thriving in 1924. And if anyone wants to know more about the Immigration Act of 1924, see here:

https://en.wikipedia.org/wiki/Immigration_Act_of_1924

And contrary to what you claim:

The act had negative economic effects. Economists hav
wii1dr wii1dr 35 minutes ago
FYI:In 401k investors can get on and join an aggressive approach, moderate or be in a conservative program. You can be in because of emotion, proper DD, and/or through financial advice. You can jump in an opportunity when you see a good based on your analysis. But to see things on what if the sky mi
NVDA
janice shell janice shell 39 minutes ago
"That looks like a piece of watermelon!!" And the woman says it's a "perfect breakfast for two"??? On what planet??
Gusher405 Gusher405 44 minutes ago
Truth 😂

Lets Go DBMM!
DBMM
Stockman1010101 Stockman1010101 45 minutes ago
Tuesday will be quite a day for both stocks. As they say sky's the limit now. I would not want to be a short at this time. That is why some smart big shorts covered in after hours today running AMC to $5.25 from $4.80 and GME to $23 from $19.
We should see more runup in pre-market in pre-mark
AMC GME
ty3 ty3 47 minutes ago
Reading my mind!
AGBA

Your Recent History

Delayed Upgrade Clock